Public Policy Analysis & Opinion I WONDER WHAT DeMOSS KNOWS Who said insurance public policy is dull and colorless? The phone rings. “Hey, Sarge, it’s me. I know some guys who know some people who think you should know something. Usual rules?” And so it starts again. When I recognize that voice, I know our conversation is going to be intriguing but probably stressful. The man I know as “Chet
General Articles
Agency leaders gather to recognize the extraordinary and share insights on the industry This spring, insurance agency leaders from throughout North America converged on Indianapolis for the annual Rough Notes Agency of the Year Dinner, Community Service Award presentation, and Rough Notes Agent Editorial Advisory Board meeting. More than three dozen professionals took part. The dinner kicked off with a humorous retrospective of The Rough Notes Company titled “The Rest
Kids’ Chance offers scholarships to youths affected by parents’ work-related injuries or deaths Regardless of the town meeting’s agenda, The Simpsons’ Helen Lovejoy, wife of Reverend Timothy Lovejoy, can be heard screaming her catchphrase: “Won’t somebody please think of the children?!” Most of us can only imagine standing in the shoes of a child who has learned that a parent has been killed or seriously injured in an accident at
Understanding issues lets agents help clients address risks The greatest threat to the cannabis industry—even bigger than the threat of federal seizure and prosecution—is the ever-increasing potential for product liability claims and litigation. Defective and contaminated products are inevitable, and plaintiffs’ attorneys are on the lookout. Nevertheless, cannabis product liability risks may be minimized with industry-specific knowledge, appropriate planning, and specialized insurance programs. Agents and brokers who understand the issues
Public Policy Analysis & Opinion Researchers explore a prime driver of U.S. healthcare financial losses Insurance mechanisms transfer and spread the risk of financial loss across the largest population possible. Too often, policymakers insist on dismissing personal or institutional financial losses as mere “spending.” Of the ten countries studied by researchers, the United States applies the lowest level of public interest oversight to pharmaceutical pricing. According to a recent study
